| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Guardant Health, Inc.$132.18
+3.07 (+2.38%)
F 14Pipeline Score Tools & Services · Commercial
Market Cap
15.77 B
EPS
-3.40
P/E Ratio
-
Value Trade
269.68 M
SEC Financials
Q1 2026Dilution Risk
Revenue
301.67 M
R&D Expenses
91.04 M
Operating CF
-65.62 M
Total Assets
1.92 B
Total Liabilities
2.10 B
Equity
-181.07 M
D/E Ratio
12,345
22.24 %
Week
29.69 %
1 Month
10.14 %
3 Month
19.25 %
6 Month
-3.01 %
5 Year
328.65 %
All Time
Cash Data
Cash Position
1.10 B
Monthly Burn
21.87 M
Runway
49 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.05 M
52 Week Range
37.73 - 121.01
% held by Insiders
3.86 %
% held by Institutions
104.18 %
Enterprise Value
16.37 B
Total Shares
131.17 M
Short %
10.36 %
Float Shares
126.19 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F14
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 11%
Mid Cap (rank 806 of 905)
Percentile RankGuardant Health, Inc. Common Stock has significant pipeline risk (14/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Guardant Health, Inc. (GH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
GH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
GH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GHGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
Guardant Health has received FDA approval for its Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS®. This approval marks a significant advancement in personalized medicine, allowing for better-targeted therapies. The collaboration aims to improve patient outcomes by providing more precise treatment options.
Read more →GHGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health, alongside collaborators, will present 38 abstracts at the 2026 ASCO Annual Meeting. These abstracts will showcase the breadth and expanded clinical utility of Guardant's liquid biopsy tests, enhanced by their InfinityAI technology. This presentation aims to highlight advancements in cancer diagnostics and treatment monitoring.
Read more →GHAmerican Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
The American Cancer Society has updated its colorectal cancer screening guidelines to include Guardant Health's Shield blood test. This endorsement is expected to enhance early detection efforts for colorectal cancer. The inclusion of the Shield test reflects a growing recognition of non-invasive screening methods in cancer care.
Read more →GHFDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
The FDA has approved the new Guardant360 Liquid CDx, marking it as the largest liquid biopsy panel available. This approval expands its footprint by 100 times, significantly enhancing diagnostic capabilities in oncology. The approval reflects the FDA's confidence in the technology's effectiveness in providing critical insights for patient care.
Read more →GHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The details of the grants and their implications for the company were not provided in the article. This announcement is part of the company's compliance with Nasdaq regulations.
Read more →GHGuardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health has reported its financial results for the first quarter of 2026, alongside an increase in its revenue guidance for the year. The company aims to provide better forecasts based on its recent performance. Further details on the financial specifics were not disclosed in the article.
Read more →GHGuardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Guardant Health has received FDA approval for its Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant). This approval specifically targets patients with ER+/HER2- advanced breast cancer who have ESR1 mutations. The collaboration aims to enhance treatment options for this patient population.
Read more →GHGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
Guardant Health has entered a multi-year strategic collaboration with Nuvalent to advance the development of companion diagnostics and support the commercialization of targeted cancer therapies. This partnership aims to leverage the Guardant Infinity™ platform, which offers both tissue and liquid biopsy options, enhancing precision in oncology treatments.
Read more →GHGuardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. has announced its participation in several upcoming investor conferences, including the BofA Securities 2026 Healthcare Conference and the William Blair 46th Annual Growth Stock Conference. These events will provide the company with a platform to discuss its advancements in precision oncology and engage with investors. Live and archived webcasts will be available on their website.
Read more →GHGuardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
Guardant Health, a precision oncology company, will report its financial results for Q1 2026 on May 7, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be available via webcast. The company emphasizes its commitment to enhancing cancer care through innovative testing and analytics.
Read more →GHGuardant Health to Participate in Upcoming Investor Conferences - February 3, 2026
Guardant Health, a precision oncology company, has announced its participation in upcoming investor conferences. The company aims to enhance investor engagement and showcase its advancements in cancer therapies. Interested parties can access live and archived webcasts of the sessions through the company's website. Guardant Health continues to focus on improving cancer outcomes through innovative testing methods.
Read more →GHGuardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Guardant Health, Inc. has announced that it will report its financial results for the fourth quarter and full year 2025 on February 19, 2026. The report will be released after market close, followed by a conference call at 1:30 p.m. Pacific Time. The event will be available for live streaming and later replay on the company’s website.
Read more →GHGuardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Guardant Health has received FDA approval for Guardant360® CDx as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from encorafenib treatment. This approval is based on positive results from the Phase 3 BREAKWATER trial, which showed improved survival rates with encorafenib-based therapies. The test allows for non-invasive genomic testing, facilitating timely treatment decisions.
Read more →GHGuardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Guardant Health has entered a multi-year strategic collaboration with Merck to develop companion diagnostics using the Guardant Infinity Smart platform. This partnership aims to enhance the development and commercialization of Merck's oncology portfolio, emphasizing the importance of biomarkers in therapy selection. The collaboration is expected to accelerate the delivery of innovative cancer therapies.
Read more →Competitive Position
How GH ranks across every disease it competes inCompetitive Position is a premium feature
See how GH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial